Abstract
Valaciclovir (Valtrex), the L-valyl ester of acyclovir, is undergoing clinical development for the treatment and suppression of herpesviral diseases. The absolute bioavailability of acyclovir from valaciclovir and the metabolic disposition of valaciclovir were investigated with healthy volunteers in two separate studies. In a randomized, crossover study, 12 fasting healthy volunteers each received 1,000 mg of oral valaciclovir and a 1-h intravenous infusion of 350 mg of acyclovir. The mean absolute bioavailability of acyclovir was 54.2%, a value three to five times that obtained previously with oral acyclovir. A similar estimate of 51.3% was made from urinary recovery of acyclovir. In the second study, four fasting volunteers received a single oral dose of 1,000 mg of [14C]valaciclovir. The majority of plasma radioactivity was accounted for by acyclovir, with very low plasma valaciclovir concentrations (mean maximum concentration of drug in plasma = 0.19 microM), which were undetectable after 3 h postdose. By 168 h, more than 90% of the administered radioactive dose was recovered, with approximately 45% in urine and 475 in feces. More than 99% of the radioactivity recovered in urine corresponded to acyclovir and its known metabolites, 9-(carboxymethoxymethyl)guanine and 8-hydroxy-9- [(2-hydroxyethoxy)methyl]guanine, with valaciclovir accounting for less than 0.5% of the dose. Acyclovir, but no valaciclovir, was detected in fecal samples. These studies show that after oral administration to humans, valaciclovir is rapidly and virtually completely converted to acyclovir to provide a high level of acyclovir bioavailability in comparison with that following oral administration of acyclovir. The plasma acyclovir exposure obtained following oral administration of valaciclovir is similar to that achieved with doses of intravenous acyclovir, which are effective in the treatment and suppression of the less susceptible herpesviral diseases.
Full Text
The Full Text of this article is available as a PDF (189.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Balfour H. H., Jr, Chace B. A., Stapleton J. T., Simmons R. L., Fryd D. S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989 May 25;320(21):1381–1387. doi: 10.1056/NEJM198905253202105. [DOI] [PubMed] [Google Scholar]
- Burnette T. C., de Miranda P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab Dispos. 1994 Jan-Feb;22(1):60–64. [PubMed] [Google Scholar]
- Jacobson M. A., Gallant J., Wang L. H., Coakley D., Weller S., Gary D., Squires L., Smiley M. L., Blum M. R., Feinberg J. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 1994 Jul;38(7):1534–1540. doi: 10.1128/aac.38.7.1534. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kulka M., Wachsman M., Miura S., Fishelevich R., Miller P. S., Ts'o P. O., Aurelian L. Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5. Antiviral Res. 1993 Feb;20(2):115–130. doi: 10.1016/0166-3542(93)90002-z. [DOI] [PubMed] [Google Scholar]
- Meyers J. D., Reed E. C., Shepp D. H., Thornquist M., Dandliker P. S., Vicary C. A., Flournoy N., Kirk L. E., Kersey J. H., Thomas E. D. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988 Jan 14;318(2):70–75. doi: 10.1056/NEJM198801143180202. [DOI] [PubMed] [Google Scholar]
- O'Brien J. J., Campoli-Richards D. M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar;37(3):233–309. doi: 10.2165/00003495-198937030-00002. [DOI] [PubMed] [Google Scholar]
- Prentice H. G., Gluckman E., Powles R. L., Ljungman P., Milpied N., Fernandez Rañada J. M., Mandelli F., Kho P., Kennedy L., Bell A. R. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994 Mar 26;343(8900):749–753. doi: 10.1016/s0140-6736(94)91835-x. [DOI] [PubMed] [Google Scholar]
- Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
- Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]
- de Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):29–37. doi: 10.1093/jac/12.suppl_b.29. [DOI] [PubMed] [Google Scholar]
- de Miranda P., Burnette T. C. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab Dispos. 1994 Jan-Feb;22(1):55–59. [PubMed] [Google Scholar]
- de Miranda P., Good S. S., Laskin O. L., Krasny H. C., Connor J. D., Lietman P. S. Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther. 1981 Nov;30(5):662–672. doi: 10.1038/clpt.1981.218. [DOI] [PubMed] [Google Scholar]